The NIH on Autoimmune Disease: An Invisible Epidemic
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
Menu
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
The Blog – Here to Help From keeping up with the latest players in digital health to providing DIY health tips, we cover a lot of ground. Explore what we have to offer here in our blog. Autoimmune Connect Thought Leadership Patient Advocacy – Autoimmune Connect Autoimmune Connect is the
May 2022 Report This May 2022 549-page NIH report represents a significant breakthrough in autoimmune research focus. Its recommendations have major downstream implications for CDC statistics, basic research, R&D, medical education & clinical guidelines. Funded and launched in 2019, before the pandemic but even more relevant since COVID-19 spotlighted post-viral
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
Digitally enabled, virtual first care (V1C) offers a potential solution to convoluted autoimmune patient journeys. V1C especially offers significant advantages for autoimmune and inflammatory disease (AIID) patients in accessing specialized care. Virtual specialist practices get patients to a rheumatologist or gastroenterologist much faster (days rather than months) and with less
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
The Visible Chronic Disease Epidemic Click the arrows next to the slide to view the sources. The chronic disease population has grown substantially in recent years since modern medicine has extended the human lifespan. Depending on sources, 40-60% of Americans (128-140M people) have one or more chronic health conditions. Moreover,
Slow & Uncoordinated Path to Diagnosis & Treatment Today, autoimmune patient journeys are typically long, convoluted, and frustrating; from first awareness of symptoms to scheduling medical visits, diagnosis, treatment, and long-term care. Since many autoimmune & inflammatory diseases (AIIDs) emerge in youth or middle age and last a lifetime, the
Autoimmune Patient Journey The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Unlike cancer, diabetes, and heart disease, there are no population screening nor public health education programs for AIIDs. This blocks the path to early diagnosis and preventative autoimmune care. As early symptoms fluctuate
Autoimmune Diseases are Siloed by Specialty Click the arrows next to the slide to view the sources. Looks a mess, doesn’t it? It is! Autoimmune diseases are scattered across many different medical specialties, creating a siloed landscape in which patients must coordinate and navigate for themselves. This illustration maps high-prevalence
